February 2, 2016 – The Institute for Clinical and Economic Review (ICER) announced today that it will develop a report assessing the comparative effectiveness and value of diabetes prevention programs. The report will be the subject of the June 24, 2016 public meeting of the California Technology Assessment Forum (CTAF).
ICER’s report will include a systematic review of the published evidence, an analysis of the costs to implement diabetes prevention programs and their potential budgetary impact, and a summary of the policy landscape for diabetes prevention programs in California. The policy analysis will identify key programs, components that contribute to success, and examine the legal, regulatory, and financial landscape for these programs.
The report will form the basis for deliberation and discussion at the public meeting, where the CTAF Panel will vote on key questions raised in the report and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
A preliminary scoping document will be posted to the CTAF website for public comment on or about March 3, 2016. After the scoping document is posted, stakeholders will have one week to submit suggestions and refinements to ensure that the report provides a comprehensive analysis of the considerations and issues of greatest importance.
Meeting details and registration information will be posted to the CTAF website as they become available.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.